MetaVia Inc. (NASDAQ:MTVA – Get Free Report) saw a large decline in short interest in the month of June. As of June 30th, there was short interest totaling 124,038 shares, a decline of 70.1% from the June 15th total of 414,844 shares. Based on an average trading volume of 204,942 shares, the days-to-cover ratio is presently 0.6 days. Approximately 2.4% of the shares of the company are short sold.
Wall Street Analyst Weigh In
MTVA has been the topic of several research analyst reports. Wall Street Zen upgraded MetaVia to a “sell” rating in a research note on Saturday, June 20th. Weiss Ratings restated a “sell (e+)” rating on shares of MetaVia in a research note on Friday, April 24th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of MetaVia in a report on Friday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $20.00.
Get Our Latest Stock Report on MetaVia
Institutional Trading of MetaVia
MetaVia Price Performance
MTVA stock traded up $0.05 during trading on Friday, hitting $1.78. 129,086 shares of the company traded hands, compared to its average volume of 193,318. The stock’s 50-day simple moving average is $1.90 and its 200 day simple moving average is $2.61. The company has a market cap of $9.18 million, a PE ratio of -0.34 and a beta of 0.97. MetaVia has a 1 year low of $0.97 and a 1 year high of $19.03.
MetaVia (NASDAQ:MTVA – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.03). Research analysts expect that MetaVia will post -2.78 earnings per share for the current year.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
Featured Stories
- Five stocks we like better than MetaVia
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
